In the first half of 2014, drug company advertisement spending inventory

Kantar Media is a well-known media research and insights department. According to its latest data, in the first half of 2014, pharmaceutical companies accumulated a total of US$342 million in advertisements for professional medical journals, an increase of 1 percentage point over the same period.

In 2014, it was a year of resource integration. In 2015, it was a year in which the traditional field of biopharmaceuticals understood the “Internet thinking digital media”.

Looking back at the past few years in 2014, we found that Johnson & Johnson invested $23 million in ad spending only in the first six months and was the largest consumer of advertising in the pharmaceutical industry.

GSK, which has been subjected to the “Bribery & Corruption” scandal, invested $9 million, which is less than half that of Johnson & Johnson, but it has risen by 110% compared to 2013, ranking it second.

Pfizer declined from the same period of last year. Its investment was similar to that of Takeda, which was 8 million U.S. dollars, and Novartis ranked the fifth at 7 million U.S. dollars.

This ranking, compared with last year, Johnson & Johnson has always maintained the position of advertising investment NO.1 in the industry.

The difference is that the Forest Laboratories in 2013 had more investment in advertising. In February of this year, Actavis PLC (NYSE:ACT), the world’s third-largest generic drug manufacturer, announced that it passed once. Cash-plus-stock trading acquired Forest Laboratories, a brand-name drug maker, for approximately US$25 billion.

According to Kantar Media's research, the purchase of flat-media advertising pages in medical journals dropped by 2% each year to 53,094 US dollars, which is related to the rise of online media.

On the basis of treatment, oncology drug brands lead consumption, and cancer drug brand investment reached 25 million U.S. dollars, accounting for 7% of the total market share; followed by oral diabetes drugs (14 million U.S. dollars), 52% more than the same period of last year, accounting for sales. 4% of the amount.